Usa New York, Usa city Sanofi covid-19 president death Usa New York, Usa city Sanofi

Sanofi and Regeneron trial Kevzara to treat severe Covid-19

Reading now: 204
www.pharmaceutical-technology.com

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Sanofi and Regeneron Pharmaceuticals have initiated a clinical programme of rheumatoid arthritis drug Kevzara (sarilumab) to treat hospitalised patients with severe Covid-19 coronavirus infection.

Kevzara is a fully-human monoclonal antibody, which inhibits the interleukin-6 (IL-6) pathway. The drug is being co-developed by Sanofi and Regeneron.

IL-6 is associated with the overactive inflammatory response in the lungs of severely or critically ill Covid-19 patients. According to the companies, the trial will be initially performed at medical centres in New York, US.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA